2024
-
October 11, 2024 R & D PDF150 KB
-
September 24, 2024 Pharmaceuticals PDF159 KB
-
September 18, 2024 R & D PDF147 KB
-
September 06, 2024 R & D PDF261 KB
-
August 21, 2024 Pharmaceuticals PDF373 KB
Antineoplastic agents Released "Jaypirca® Tablets 50 mg, Jaypirca® Tablets 100 mg"
-
August 20, 2024 Management & Finance PDF131 KB
Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation
-
August 07, 2024 Management & Finance
Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2024
-
August 07, 2024 Management & Finance PDF389 KB
-
July 30, 2024 Corporate PDF277 KB
Nippon Shinyaku Selected as a Constituent of the FTSE4Good Index Series
-
July 22, 2024 Management & Finance PDF171 KB
Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation
-
July 01, 2024 Corporate PDF284 KB
Nippon Shinyaku Selected as a Constituent of the SOMPO Sustainability Index
-
June 24, 2024 Pharmaceuticals PDF325 KB
-
May 27, 2024 R & D PDF117 KB
-
May 27, 2024 Management & Finance PDF291 KB
The 7th Five-Year Medium-Term Management Plan "For Global Growth Beyond the Cliff”
-
May 24, 2024 Management & Finance PDF147 KB
Notice Regarding Introduction of a Restricted Stock Compensation Plan
-
May 22, 2024 Pharmaceuticals PDF295 KB
Launch of VyxeosⓇ Combination for I.V. Injection for the Treatment of High-risk AML in Japan
-
May 10, 2024 Management & Finance
Outline of Consolidated Financial Results for the Year Ended March 31, 2024
-
April 16, 2024 R & D PDF282 KB
-
April 04, 2024 R & D PDF266 KB
Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System
-
March 26, 2024 Pharmaceuticals PDF297 KB
Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan
-
March 26, 2024 Pharmaceuticals PDF303 KB
-
March 25, 2024 R & D PDF279 KB
-
March 06, 2024 R & D PDF262 KB
-
February 27, 2024 R & D PDF252 KB
-
February 09, 2024 R & D PDF239 KB
-
February 09, 2024 Management & Finance
Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2023
-
January 22, 2024 R & D PDF263 KB